Humana Inc. (NYSE:HUM), renowned health insurer, experienced mixed outcomes over the course of this period. The company's stock saw upsurge of about 3.1%, generating interest among investors and underwent an analyst upgrade leading to high trading volume.
Nisa Investment Advisors LLC sold off their shares, as did
Financial Partners Group LLC, and
Ballentine Partners LLC. Humana's stock was purchased by
Assenagon Asset Management S.A and
Crossmark Global Holdings Inc. The financial forecast for Humana Inc. is positive with raised price target from
Barclays and
Piper Sandler. However,
Medicare Advantage ratings cut hit the stock hard, leading to considerable membership slump for 2025 and stock diving, despite dispute by Humana to reverse the decision. Yet,
Susan Diamond, Humana CFO announced her departure causing more changes to Humana's high-level management. In a positive development,
Michelle O'Hara was appointed as Chief Human Resources Officer and
Japan Mehta as Chief Information Officer to lead digital transformation. It also made strategic alliances, like with
Evergreen Nephrology to improve health outcomes. Humana continued to hold substantial holdings for
Sustainable Insight Capital Management LLC. However, the company's overall performance was less than stellar. The Humana stock price was expected to rise but experienced a 30% loss in Q3. Still, the health insurer remains a key player as despite shareholder losses over the year, and a whistleblowing investigation into the company, experts suggest holding the stock.
Humana HUM News Analytics from Wed, 31 Jul 2024 07:00:00 GMT to Sat, 25 Jan 2025 09:20:39 GMT -
Rating 0
- Innovation -3
- Information 8
- Rumor -4
